Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PolandBack to Poland

Clinical trials in Slupsk – page 2

45 clinical trials in Slupsk, Poland across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Slupsk at a glance
45
clinical trials
  • Paediatric trials0
  • Research sites1
Type of trial
Recruitment status
Quick filters

45 trials in Slupsk

Open in trial search

Plasma cell myeloma refractory

Recruiting

Study Comparing Mezigdomide, Bortezomib, and Dexamethasone with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Celgene Corp.

Malignant melanoma

Recruiting

Study to Compare Fianlimab and Cemiplimab Combination with Pembrolizumab in Patients with High-Risk Melanoma After Surgery

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Chronic lymphocytic leukaemia+2

Recruiting

Study on Human Normal Immunoglobulin and Sodium Chloride to Prevent Infections in Patients with Chronic Lymphocytic Leukemia

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Grifols Therapeutics LLC

Plasma cell myeloma

Not yet recruiting

Dapagliflozin for Primary Cardioprotection in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation – A Randomized Phase 2 Study

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Instytut Hematologii I Transfuzjologii

Embolism

Not yet recruiting

A study to evaluate the effectiveness of REGN7508 for preventing blood clots in adults with solid tumors undergoing cancer treatment.

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:REGN7508
  • Sponsor:Regeneron Pharmaceuticals Inc.

Malignant melanoma

Not yet recruiting

Study Comparing MK-7684A (Vibostolimab and Pembrolizumab) with Pembrolizumab for Adults and Children with High-Risk Melanoma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Gastric cancer+1

Not recruiting

Study on the Effectiveness and Safety of AZD0901 Compared to Standard Treatments for Adults with Advanced Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:AZD0901
  • Sponsor:AstraZeneca AB

Bladder cancer

Not recruiting

Study of Pembrolizumab and BCG for Patients with High-Risk Non-Muscle Invasive Bladder Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Chronic obstructive pulmonary disease

Not recruiting

Study of Astegolimab Treatment in Patients with Chronic Obstructive Pulmonary Disease (COPD) to Reduce Disease Flare-ups

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Astegolimab
  • Sponsor:F. Hoffmann-La Roche AG

Atrial fibrillation+5

Not recruiting

Study of Allopurinol to Reduce Cardiovascular Events in High-Risk Patients with Heart Disease and Long-COVID Syndrome

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Allopurinol
  • Sponsor:Agencja Badań Medycznych

Depression+2

Not recruiting

Study on the Effects of Sertraline on Anxiety and Depression in Heart Failure Patients with Preserved Ejection Fraction

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Sertraline
  • Sponsor:Medical University Of Gdansk

Prostate cancer

Not recruiting

Study on Enzalutamide and Leuprorelin Acetate for Men with High-Risk Nonmetastatic Prostate Cancer After Treatment

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Medivation Inc.

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Slupsk

What the registry says about research in the country

01 Oncology & Hematology

Innovative research focusing on blood cancers and solid tumors, including groundbreaking studies in multiple myeloma, lymphomas, and leukemia treatments.

  • Multiple Myeloma Studies
  • Lymphoma Research
  • Chronic Lymphocytic Leukemia

Novel combination therapies and targeted treatments are being evaluated for improved patient outcomes.

02 Respiratory Medicine

Clinical investigations targeting chronic respiratory conditions, with emphasis on developing enhanced treatment options for asthma and COPD management.

  • Asthma Control Studies
  • COPD Management
  • Inhaler Therapy Research

Focus on improving lung function and reducing exacerbations in respiratory disorders.

03 Cardiovascular Health

Research exploring the intersection of heart failure and mental health, investigating new approaches to treating complex cardiovascular conditions.

  • Heart Failure Studies
  • Depression in Cardiac Patients
  • Endothelial Function Research

Investigating the relationship between psychological well-being and cardiac outcomes.

Back to PolandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.